<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

VeriStrat® Proteomic Test

Identifies a chronic inflammatory disease state associated with aggressive cancer.


Measure your patient’s immune response to lung cancer.

VeriStrat® provides a personalized view of each patient's disease state within 72 hours. Test results are predictive of outcomes, independent of ECOG performance status, mutation status, PD-L1 expression, and treatment choice.1,2,3,4,5

What is the VeriStrat® test?

  • Blood-based proteomic test that provides a personalized view of each patient's disease state
  • Measures acute phase proteins and the acute phase response which indicates chronic inflammation and a more aggressive cancer
  • Impacts treatment strategy and facilitates disease state monitoring

Interpreting VeriStrat® Results

VeriStrat Good results indicate a disease state that is more likely to respond to standard of care treatment.

Download VeriStrat good report

VeriStrat Poor results indicate a chronic inflammatory disease state. These patients may benefit from an alternative treatment strategy2,6, including:

  • Clinical trials and novel combination therapies
  • Broad genomic profiling for rare mutations
  • Faster time to treatment, if active therapy is being considered
  • Palliative care

Download VeriStrat poor report

Data demonstrate VeriStrat Good patients survive 2–3 times longer than VeriStrat Poor patients, independent of treatment choice.









VeriStrat is a robust, blood-based test validated across 85+ studies with over 6,600 patients.

Identifying Treatment Strategies for the VeriStrat Poor Disease State

Patients may benefit from novel therapeutic combinations in clinical trials.

MARQUEE2 - EGFR mut Cohort: erlotinib +/- tivantinib


AVEO P06162 Study6: gefitinib +/- ficlatuzumab


The Veristrat® Proteomic Test is Covered by Medicare And Many Private Payers.

Learn more about our reimbursement

“It is recommended that all physicians caring for patients with lung cancer should begin conversations about the patient’s prognosis and goals of care at the time of the diagnosis, and continue these throughout the course of the illness.”

- CHEST Grade IB Recommendation9

Case Studies

Learn how some of the industry’s leading experts are using Biodesix Lung Reflex® testing in their practice.


Jonathan Kurman, MD

Froedtert & the Medical College of Wisconsin


Michael Pritchett, DO, MPH

Chest Center of the Carolines at FirstHealth of the Carolinas

Patients prefer to understand their cancer prognosis and expected outcome10

  • Improved disease knowledge results in better quality care and quality of life for both the patient and caregiver.11,12
  • Providing detailed information on prognosis decreases patient anxiety.​
  • Clinical guidelines encourage clear communication of prognosis with patients, caregivers and their families.

Interested in ordering a test kit?


Get in touch

Contact us

Data library

Discover more
  1. Fidler MJ, et al. BMC Cancer (2018) 18:310
  2. Buttigliero C, et al. The Oncologist. 2018 Aug 23.
  3. Grossi, F, et al. J Thorac Oncol. 2017; 12 (S1322 P3.02c-074).
  4. Grossi, F, et al. Br J Cancer. 2017 Jan 3; 116(1):36-43.
  5. Rich P, et. al 2019 (Multidisciplinary Thoracic Cancers Symposium poster).
  6. Mok T, et al. J Thorac Oncol. 2016 Oct; 11(10):1736-1744.
  7. Grossi, et al. Lung Cancer 117 (2018): 64–69.
  8. Carbone DP, et al. J Thorac Oncol. 2012;7(11):1653-1660.
  1. Reprinted from CHEST, 143 /5(Suppl), Detterbeck et al., Executive Summary Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines / Palliative and End-of-Life Care in Lung Cancer, Page No. 37S, Copyright (2013), with permission from Elsevier.
  2. Hagerty et al. Journal of clinical oncology 22, no.9 (2004): 1721-1730.
  3. Wright et al. Jama 300,no.14 (2008): 1665-1673.
  4. Sullivan et al. Journal of palliative medicine 10, no.4 (2007): 882-893.